Select Publications
Chanan-Khan A et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006;24(34):5343-9. Abstract
Czuczman MS et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Proc ASCO 2008;Abstract 8509.
Ferrajoli A et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-7. Abstract
Ferrajoli A et al. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia carrying unfavorable chromosomal abnormalities. Proc ASH 2007;Abstract 754.
Friedberg JW et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26(2):204-10 Abstract.
Kahl B et al. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Proc ASH 2007;Abstract 1351.
Moutouh-de Parseval LA et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25(31):5047. No abstract available
Robinson KS et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26(27):4473-9. Abstract
Rummel MJ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005;23(15):3383-9. Abstract
Van Oers M et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 Intergroup trial. Blood 2006;108(10):3295-301. Abstract
Weide R et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48(7):1299-306. Abstract
Witzig TE et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Proc ASCO 2007;Abstract 8066.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Bruce D Cheson, MD
- Select publications
Hagop M Kantarjian, MD
- Select publications
Sagar Lonial, MD
- Select publications
